Human Genome Epidemiology Literature Finder
|
Records 1 - 13 (of 13 Records) |
| Query Trace: Hyperglycemia and PIK3CA[original query] |
|---|
| A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 2013 May 119 (10): 1823-31. Fury Matthew G, Sherman Eric, Ho Alan L, Xiao Han, Tsai Frank, Nwankwo Oby, Sima Camelia, Heguy Adrian, Katabi Nora, Haque Sofia, Pfister David |
| A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 2016 Sep . Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R, Aghajanian Carol |
| Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer discovery 2017 Mar . Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo |
| A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Investigational new drugs 2018 Apr . Aghajanian Carol, Bell-McGuinn Katherine M, Burris Howard A, Siu Lillian L, Stayner Lee-Ann, Wheler Jennifer J, Hong David S, Kurkjian Carla, Pant Shubham, Santiago-Walker Ademi, Gauvin Jennifer L, Antal Joyce M, Opalinska Joanna B, Morris Shannon R, Infante Jeffrey |
| Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine 2019 5 380 (20): 1929-1940. André Fabrice, Ciruelos Eva, Rubovszky Gabor, Campone Mario, Loibl Sibylle, Rugo Hope S, Iwata Hiroji, Conte Pierfranco, Mayer Ingrid A, Kaufman Bella, Yamashita Toshinari, Lu Yen-Shen, Inoue Kenichi, Takahashi Masato, Pápai Zsuzsanna, Longin Anne-Sophie, Mills David, Wilke Celine, Hirawat Samit, Juric Dejan, |
| Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. International journal of cancer 2019 Nov . Myers Andrea P, Konstantinopoulos Panagiotis A, Barry William T, Luo Weixiu, Broaddus Russell R, Makker Vicky, Drapkin Ronny, Liu Joyce, Doyle Austin, Horowitz Neil S, Meric-Bernstam Funda, Birrer Michael, Aghajanian Carol, Coleman Robert L, Mills Gordon B, Cantley Lewis C, Matulonis Ursula A, Westin Shannon |
| Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic oncology reports 2020 Feb 31 100532. Santin Alessandro D, Filiaci Virginia, Bellone Stefania, Ratner Elena S, Mathews Cara A, Cantuaria Guilherme, Gunderson Camille C, Rutledge Teresa, Buttin Barbara M, Lankes Heather A, Frumovitz Michael, Khleif Samir N, Huh Warner K, Birrer Michael |
| Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. Breast cancer research and treatment 2022 11 197 (2): 369-376. Burnette Sarah E, Poehlein Emily, Lee Hui-Jie, Force Jeremy, Westbrook Kelly, Moore Heather |
| Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 9 JCO2400110. Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Jur |
| SGLT2 inhibition improves PI3K? inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Breast cancer research and treatment 2024 8 . Manuel Ruiz Borrego, Yen-Shen Lu, Felipe Reyes-Cosmelli, Yeon Hee Park, Toshinari Yamashita, Joanne Chiu, Mario Airoldi, Nicholas Turner, Luis Fein, Farhat Ghaznawi, Jyotika Singh, Kristyn Pantoja, Christian Schnell, Murat Akdere, Stephen Ch |
| Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Current cancer drug targets 2024 1 . Yi Wang, Xianling Du, Hongqiang Xin, Ruimin |
- Page last reviewed:Feb 1, 2024
- Content source: